Effect of sodium selenium administration on functional and cognitive scores in ischemic stroke

Investigation of the sodium selenium administration on the level of inflammatory factors, oxidative stress and functional and cognitive scores in acute ischemic stroke patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170104031773N3

Enrollment

Registered

2019-06-09

Start date

2019-04-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: 500µg Selenase injection vial contains 1.67mg sodium selenite pentahydrate (German biosyn company), receiving a dose of 2000 µg after admission and then 1000 µg for 5 days. Interventio

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with acute stroke

Exclusion criteria

Exclusion criteria: Receiving antioxidants constantly (such as vitamin C and E) Receiving anti-inflammatory drugs constantly(steroids, nonsteroidal anti-inflammatory) Suffered from HIV and neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis) Systemic diseases such as Diabetes Mellitus, Renal Failure, Malignant Melanoma, Uremia,Myopathy, and Congestive Heart Failure Loss of consciousness level due to any reason except stroke (such as shock, alcohol consumption or intoxication)

Design outcomes

Primary

Measure	Time frame
The level of tumor necrosis factor alpha(TNF-a). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood sample.;The level of superoxide dismutase (SOD). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood Sample.;The level of glutathione peroxidase(GPx). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood Sample.	—

Measure

Time frame

The level of tumor necrosis factor alpha(TNF-a). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood sample.;The level of superoxide dismutase (SOD). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood Sample.;The level of glutathione peroxidase(GPx). Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Blood Sample.

—

Secondary

Measure	Time frame
Motor function and verbal. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: National Institues of Health Stroke Scale Questionnaire.;Cognitive performance. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Mini Mental State Examination Questionnaire.;Degree of disability. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Modified Rankin Scale Questionnaire.	—

Measure

Time frame

Motor function and verbal. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: National Institues of Health Stroke Scale Questionnaire.;Cognitive performance. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Mini Mental State Examination Questionnaire.;Degree of disability. Timepoint: At the beginning of the study (before the intervention), 1 month after the start of taking sodium selenite. Method of measurement: Modified Rankin Scale Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Simani

Shahid Beheshti University of Medical Sciences

l.simani90@sbmu.ac.ir+98 21 5102 5182

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026